ClinicalTrials.gg
CompletedNCT00303472Updated Dec 16, 2013Results posted

Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)

A Phase 2 interventional study of Romiplostim in Thrombocytopenia, MDS and Myelodysplastic Syndromes, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-16.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing romiplostim in Thrombocytopenia — 9 open to participants now, 9 under way, 3 of them phase 3. romiplostim · Thrombocytopenia.

Enrollment
13th of 41
72 · median 62
Started
2006
with 4 others
Phase 2
20 of 41
5 open now
Registered
8th of 41
by date
Lead sponsor
18 of 41
Amgen

Among the 41 studies testing romiplostim in Thrombocytopenia, this one is the 13th largest by enrollment, is one of 5 that started in 2006, is one of 20 in phase 2, and was the 8th registered.

Thrombocytopenia

484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.

Browse Thrombocytopenia studies →

Open to participants now

9 of the 41 studies testing romiplostim in Thrombocytopenia are open now, in 3 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About romiplostim

romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing romiplostim in Thrombocytopenia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of romiplostim in thrombocytopenic patients with low or Intermediate-1 risk MDS. In addition, the study will evaluate the platelet response to romiplostim.

03

Conditions studied

  • Thrombocytopenia
  • MDS
  • Myelodysplastic Syndromes
  • Refractory Cytopenias

Keywords

  • MDS
  • Myelodysplastic Syndromes
  • Refractory Cytopenias
  • Thrombocytopenia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of MDS using the World Health Organization classification
  • Low or Intermediate-1 risk MDS using the International Prognostic Scoring System (IPSS)
  • The mean of two counts taken during the screening period must be ≤ 50 x 10\^9/L, with no individual count > 55 x 10\^9/L (The mean platelet counts of 5 subjects enrolled at the maximum tolerated dose (MTD) must be ≤ 20 x 10\^9/L). Standard of care platelet assessments taken prior to may be used as 1 of the 2 counts taken within 3 weeks prior to study day 1.
  • Must be ≥ 18 years of age at the time of obtaining informed consent
  • (ECOG) performance status of 0-2 at the time of screening
  • Adequate Liver Function, as evidenced by a serum ≤ 1.5 times the laboratory normal range (except for patients with a confirmed diagnosis of Gilbert's Disease), (ALT) ≤ 3 times the laboratory normal range, and aspartate aminotransferase (AST) ≤ 3 times the laboratory normal range
  • A serum creatinine concentration ≤ 2 mg/dL (≤ 176.6 µmol/L)
  • Before any study-specific procedure, the appropriate written informed consent must be obtained (see Section 12.1)

Exclusion criteria

Exclusion Criteria:

  • Currently receiving any treatment for MDS other than transfusions and erythropoietic growth factors. If granulocyte growth factors are currently being received, they cannot be used on or after study day 1
  • bleeding within 2 weeks prior to screening (eg, gastrointestinal (GI) bleeds, intracranial hemorrhage)
  • Prior (other than controlled prostate cancer, in situ cervical cancer or basal cell cancer of the skin) unless treated with curative intent and without evidence of disease for ≥ 3 years before screening
  • Prior history of bone marrow transplantation
  • Persistent peripheral blood monocytosis (≥ 3 months with an absolute monocyte count > 1,000/µL)
  • Unstable angina, congestive heart failure ( [NYHA] > class II), uncontrolled hypertension (diastolic > 100 mmHg), uncontrolled cardiac arrhythmia, or recent (within 1 year) myocardial infarction
  • Received Anti-Thymocyte Globuline (ATG) within 6 months of screening
  • Received hypomethylating agents, immunomodulating agents, histone deacetylase inhibitors, cyclosporine or mycophenolate within 6 weeks of screening
  • Received interleukin (IL)-11 (oprelvekin) within 4 weeks before screening
  • Concurrent use of granulocyte growth factors (i.e. granulocyte-colony stimulating factor [G-CSF; Neupogen, Granocyte], pegfilgrastim [Neulasta], granulocyte macrophage-colony stimulating factor [GM-CSF; Leukine, Prokine, Sargramostim])
  • Have ever previously received recombinant thrombopoietin (rTPO), pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), eltrombopag, or romiplostim
  • Less than 4 weeks since receipt of any therapeutic drug or device that is not Food and Drug Administration (FDA) approved for any indication
  • Other procedures are excluded
  • History of arterial thrombosis (eg, stroke or ) in the past year
  • History of venous thrombosis that currently requires anti-coagulation therapy
  • Untreated B12 or folate deficiency
  • Subject is evidently pregnant (eg, positive human chorionic gonadotropin [HCG] test) or is breast feeding
  • Subject is not using adequate precautions
  • Subject has known to any recombinant E coli-derived product
  • Subject previously has enrolled in this study
  • Subject will not be available for follow-up assessment
  • Subject has any kind of disorder that compromises the ability of the subject to give written and/or to comply with study procedures
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Part A: 300 µg romiplostim

    Cohort 1 in Part A, participants received romiplostim 300 µg subcutaneously once weekly for 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.

    Drug: Romiplostim

  • Experimental
    Part A: 700 µg romiplostim

    Cohort 2 in Part A, participants received romiplostim 700 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.

    Drug: Romiplostim

  • Experimental
    Part A: 1000 µg romiplostim

    Cohort 3 in Part A, participants received romiplostim 1000 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.

    Drug: Romiplostim

  • Experimental
    Part A: 1500 µg romiplostim

    Cohort 4 in Part A, participants received romiplostim 1500 µg subcutaneously once weekly for up to 3 weeks. Participants who completed Part A could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.

    Drug: Romiplostim

  • Experimental
    Part B: 750 µg romiplostim SC QW

    Part B participants received romiplostim 750 µg subcutaneously (SC) once weekly (QW) for 8 weeks. Participants who complete Part B could continue to receive weekly injections of romiplostim for up to 1 year in the extension treatment phase.

    Drug: Romiplostim

  • Experimental
    Part B: 750 µg romiplostim SC Q2W

    Part B participants received romiplostim 750 µg subcutaneously every two weeks (Q2W) for 8 weeks. Participants who complete Part B could continue to receive injections of romiplostim for up to 1 year in the extension treatment phase.

    Drug: Romiplostim

  • Experimental
    Part B: 750 µg romiplostim IV Q2W

    Part B participants received romiplostim 750 µg intravenously (IV) once every two weeks for 8 weeks. Participants who complete Part B could continue to receive romiplostim for up to 1 year in the extension treatment phase.

    Drug: Romiplostim

Interventions

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants With Adverse Events

    The number of participants experiencing one or more adverse events during the treatment phase or extension phase of Part A.

    Time frame: Treatment period (4 weeks) plus treatment extension (1 year)

  2. Part B: Number of Participants With Adverse Events

    The number of participants experiencing one or more adverse events during the treatment phase or extension phase of Part B.

    Time frame: Treatment period (8 weeks) plus treatment extension (1 year)

Secondary outcomes

  1. Part A: Number of Participants With a Complete or Major Platelet Response

    Participants with a complete or major response during the treatment phase. A complete platelet response was defined as a platelet count ≥ 100 x 10\^9/L during the treatment phase. A major platelet response was defined as an increase in absolute platelet count of ≥ 30 x 10\^9/L for patients starting with \> 20 x 10\^9/L platelets, or an increase from ≤ 20 x 10\^9/L to \> 20 x 10\^9/L and by at least 100%. Any participant receiving rescue medication was considered a non-responder. Platelet transfusions were considered rescue medication.

    Time frame: Treatment Period (4 weeks)

  2. Part B: Number of Participants With a Complete or Major Platelet Response

    Participants with a complete or major response during the treatment phase. A complete platelet response was defined as a platelet count ≥ 100 x 10\^9/L during the treatment phase. A major platelet response was defined as an increase in absolute platelet count of ≥ 30 x 10\^9/L for patients starting with \> 20 x 10\^9/L platelets, or an increase from ≤ 20 x 10\^9/L to \> 20 x 10\^9/L and by at least 100%. Any participant receiving rescue medication was considered a non-responder. Platelet transfusions were considered rescue medication.

    Time frame: Treatment Period (8 weeks)

  3. Part A: Number of Participants With a Platelet Response Per IWG Criteria

    The number of participants with a platelet response according to the modified International Working Group (IWG) criteria. Response was defined as an absolute increase of ≥ 30 x 10\^9/L with Baseline platelet count \> 20 x 10\^9/L, or with a Baseline count ≤ 20 x 10\^9/L, increasing to above 20 x 10\^9/L and by at least 100% during the treatment or extension period and maintained for at least 8 consecutive weeks. Platelet transfusion was not considered a rescue medication but platelet counts ≤72 hours after platelet transfusion were excluded from the analysis.

    Time frame: Treatment period (4 weeks) and extension period (52 weeks).

  4. Part B: Number of Participants With a Platelet Response Per IWG

    The number of participants with a platelet response according to the modified International Working Group (IWG) criteria. Response was defined as an absolute increase of ≥ 30 x 10\^9/L with Baseline platelet count \> 20 x 10\^9/L, or with a Baseline count ≤ 20 x 10\^9/L, increasing to above 20 x 10\^9/L and by at least 100% during the treatment or extension period and maintained for at least 8 consecutive weeks. Platelet transfusion was not considered a rescue medication but platelet counts ≤72 hours after platelet transfusion were excluded from the analysis.

    Time frame: Treatment period (8 weeks) and extension period (52 weeks).

  5. Part B: Peak Platelet Count

    Peak platelet count (10\^9/L) during the treatment period.

    Time frame: Treatment Period (8 weeks)

  6. Part B: Time to First Platelet Response

    Participants achieving first platelet response according to IWG criteria, by study week. Platelet response was defined as an absolute increase of ≥ 30 x 10\^9/L with Baseline platelet count \> 20 x 10\^9/L, or with a Baseline ≤ 20 x 10\^9/L increasing the platelet count to above 20 x 10\^9/L and by at least 100% for 8 consecutive weeks. Platelet counts obtained within 72 hours of platelet transfusion were not evaluable for platelet response.

    Time frame: Treatment Period (8 weeks) and extension period (52 weeks).

  7. Part B: Duration of Platelet Response

    Duration of platelet response per IWG criteria (absolute increase of ≥ 30 x 10\^9/L with Baseline platelet count \> 20 x 10\^9/L, or with a Baseline ≤ 20 x 10\^9/L increasing the platelet count to above 20 x 10\^9/L and by at least 100% for 8 consecutive weeks).

    Time frame: Treatment Period (8 weeks) and extension period (52 weeks)

  8. Part B: Week 1 Cmax

    Maximum observed serum concentration (Cmax) of romiplostim during Week 1

    Time frame: Week 1

  9. Part B: Week 1 Ctrough

    Measured romiplostim concentration at the end of the week 1 dosing interval (Ctrough)

    Time frame: Week 1

  10. Part B: Week 1 AUC0-4

    Area under the romiplostim concentration-time curve from time zero to the last time point with quantifiable concentration (AUC0-4) during Week 1

    Time frame: Week 1

  11. Part B: Week 7 Cmax

    Maximum observed serum concentration (Cmax) of romiplostim during Week 7.

    Time frame: Week 7

  12. Part B: Week 7 Ctrough

    Measured romiplostim concentration at the end of the Week 7 dosing interval (Ctrough)

    Time frame: Week 7

  13. Part B: Week 7 AUC0-4

    Area under the romiplostim concentration-time curve from time zero to the last time point with quantifiable concentration (AUC0-4) during Week 7.

    Time frame: Week 7

  14. Part B: Week 1 Tmax

    Time at which the maximum concentration of romiplostum was observed after subcutaneous administration during Week 1

    Time frame: Week 1

  15. Part B: Week 7 Tmax

    Time at which the maximum concentration of romiplostum was observed after subcutaneous administration during Week 7

    Time frame: Week 7

07

Results

Posted Nov 19, 2010

Participant flow

First Subject Enrolled: 15-Feb-2006 Last Subject Enrolled: 29-Feb-2008

Treatment Period
Participant flow — Treatment Period
MilestonePart A: 300 µg RomiplostimPart A: 700 µg RomiplostimPart A: 1000 µg RomiplostimPart A: 1500 µg RomiplostimPart B: 750 µg Romiplostim SC QWPart B: 750 µg Romiplostim SC Q2WPart B: 750 µg Romiplostim IV Q2W
Started611111611125
Completed61111148113
Not completed0002312
Withdrew: Adverse event0000100
Withdrew: Death0001001
Withdrew: Withdrawal by subject0001010
Withdrew: Other0000101
Withdrew: Disease progression (to aml)0000100
Treatment Extension (Optional)
Participant flow — Treatment Extension (Optional)
MilestonePart A: 300 µg RomiplostimPart A: 700 µg RomiplostimPart A: 1000 µg RomiplostimPart A: 1500 µg RomiplostimPart B: 750 µg Romiplostim SC QWPart B: 750 µg Romiplostim SC Q2WPart B: 750 µg Romiplostim IV Q2W
Started6111113551
Completed1525141
Not completed5698410
Withdrew: Adverse event1010000
Withdrew: Death2010000
Withdrew: Lost to follow-up0001000
Withdrew: Physician decision0423200
Withdrew: Withdrawal by subject1012100
Withdrew: Other0242100
Withdrew: Disease progression (to aml)1000010

Outcome measures

SecondaryPart A: Number of Participants With a Complete or Major Platelet Response

Participants with a complete or major response during the treatment phase. A complete platelet response was defined as a platelet count ≥ 100 x 10\^9/L during the treatment phase. A major platelet response was defined as an increase in absolute platelet count of ≥ 30 x 10\^9/L for patients starting with \> 20 x 10\^9/L platelets, or an increase from ≤ 20 x 10\^9/L to \> 20 x 10\^9/L and by at least 100%. Any participant receiving rescue medication was considered a non-responder. Platelet transfusions were considered rescue medication.

Time frame:
Treatment Period (4 weeks)
Reported as:
Number · Participants
Part A: Number of Participants With a Complete or Major Platelet Response
ParticipantsPart A: 300 µg RomiplostimPart A: 700 µg RomiplostimPart A: 1000 µg RomiplostimPart A: 1500 µg Romiplostim
Part A: Number of Participants With a Complete or Major Platelet Response3548
SecondaryPart B: Number of Participants With a Complete or Major Platelet Response

Participants with a complete or major response during the treatment phase. A complete platelet response was defined as a platelet count ≥ 100 x 10\^9/L during the treatment phase. A major platelet response was defined as an increase in absolute platelet count of ≥ 30 x 10\^9/L for patients starting with \> 20 x 10\^9/L platelets, or an increase from ≤ 20 x 10\^9/L to \> 20 x 10\^9/L and by at least 100%. Any participant receiving rescue medication was considered a non-responder. Platelet transfusions were considered rescue medication.

Time frame:
Treatment Period (8 weeks)
Reported as:
Number · Participants
Part B: Number of Participants With a Complete or Major Platelet Response
ParticipantsPart B: 750 µg Romiplostim SC QWPart B: 750 µg Romiplostim SC Q2WPart B: 750 µg Romiplostim IV Q2W
Part B: Number of Participants With a Complete or Major Platelet Response582
SecondaryPart A: Number of Participants With a Platelet Response Per IWG Criteria

The number of participants with a platelet response according to the modified International Working Group (IWG) criteria. Response was defined as an absolute increase of ≥ 30 x 10\^9/L with Baseline platelet count \> 20 x 10\^9/L, or with a Baseline count ≤ 20 x 10\^9/L, increasing to above 20 x 10\^9/L and by at least 100% during the treatment or extension period and maintained for at least 8 consecutive weeks. Platelet transfusion was not considered a rescue medication but platelet counts ≤72 hours after platelet transfusion were excluded from the analysis.

Time frame:
Treatment period (4 weeks) and extension period (52 weeks).
Reported as:
Number · Participants
Part A: Number of Participants With a Platelet Response Per IWG Criteria
ParticipantsPart A: 300 µg RomiplostimPart A: 700 µg RomiplostimPart A: 1000 µg RomiplostimPart A: 1500 µg Romiplostim
Part A: Number of Participants With a Platelet Response Per IWG Criteria3646
SecondaryPart B: Number of Participants With a Platelet Response Per IWG

The number of participants with a platelet response according to the modified International Working Group (IWG) criteria. Response was defined as an absolute increase of ≥ 30 x 10\^9/L with Baseline platelet count \> 20 x 10\^9/L, or with a Baseline count ≤ 20 x 10\^9/L, increasing to above 20 x 10\^9/L and by at least 100% during the treatment or extension period and maintained for at least 8 consecutive weeks. Platelet transfusion was not considered a rescue medication but platelet counts ≤72 hours after platelet transfusion were excluded from the analysis.

Time frame:
Treatment period (8 weeks) and extension period (52 weeks).
Reported as:
Number · Participants
Part B: Number of Participants With a Platelet Response Per IWG
ParticipantsPart B: 750 µg Romiplostim SC QWPart B: 750 µg Romiplostim SC Q2WPart B: 750 µg Romiplostim IV Q2W
Part B: Number of Participants With a Platelet Response Per IWG241
SecondaryPart B: Peak Platelet Count

Peak platelet count (10\^9/L) during the treatment period.

Time frame:
Treatment Period (8 weeks)
Reported as:
Median · 10^9/L
Part B: Peak Platelet Count
10^9/LPart B: 750 µg Romiplostim SC QWPart B: 750 µg Romiplostim SC Q2WPart B: 750 µg Romiplostim IV Q2W
Part B: Peak Platelet Count100.0 (49.0 to 175.5)111.0 (58.0 to 453.0)83.0 (55.0 to 135.0)
SecondaryPart B: Time to First Platelet Response

Participants achieving first platelet response according to IWG criteria, by study week. Platelet response was defined as an absolute increase of ≥ 30 x 10\^9/L with Baseline platelet count \> 20 x 10\^9/L, or with a Baseline ≤ 20 x 10\^9/L increasing the platelet count to above 20 x 10\^9/L and by at least 100% for 8 consecutive weeks. Platelet counts obtained within 72 hours of platelet transfusion were not evaluable for platelet response.

Time frame:
Treatment Period (8 weeks) and extension period (52 weeks).
Reported as:
Number · Participants
Part B: Time to First Platelet Response
ParticipantsPart B: 750 µg Romiplostim SC QWPart B: 750 µg Romiplostim SC Q2WPart B: 750 µg Romiplostim IV Q2W
Week 1 Day 3010
Week 2211
Week 3010
Week 4000
Week 5 or later010
Not Observed673
SecondaryPart B: Duration of Platelet Response

Duration of platelet response per IWG criteria (absolute increase of ≥ 30 x 10\^9/L with Baseline platelet count \> 20 x 10\^9/L, or with a Baseline ≤ 20 x 10\^9/L increasing the platelet count to above 20 x 10\^9/L and by at least 100% for 8 consecutive weeks).

Time frame:
Treatment Period (8 weeks) and extension period (52 weeks)
Reported as:
Median · Weeks
Part B: Duration of Platelet Response
WeeksPart B: 750 µg Romiplostim SC QWPart B: 750 µg Romiplostim SC Q2WPart B: 750 µg Romiplostim IV Q2W
Part B: Duration of Platelet Response19.5 (8.0 to 31.0)9.0 (8.0 to 10.5)9.0 (9.0 to 9.0)
SecondaryPart B: Week 1 Cmax

Maximum observed serum concentration (Cmax) of romiplostim during Week 1

Time frame:
Week 1
Reported as:
Mean · pg/mL
Part B: Week 1 Cmax
pg/mLPart B: 750 µg Romiplostim SC QWPart B: 750 µg Romiplostim SC Q2WPart B: 750 µg Romiplostim IV Q2W
Part B: Week 1 Cmax3660 ± 30703190 ± 2360197000 ± 112000
SecondaryPart B: Week 1 Ctrough

Measured romiplostim concentration at the end of the week 1 dosing interval (Ctrough)

Time frame:
Week 1
Reported as:
Mean · pg/mL
Part B: Week 1 Ctrough
pg/mLPart B: 750 µg Romiplostim SC QWPart B: 750 µg Romiplostim SC Q2WPart B: 750 µg Romiplostim IV Q2W
Part B: Week 1 Ctrough171 ± 21235.2 ± 31.596.5 ± 127
SecondaryPart B: Week 1 AUC0-4

Area under the romiplostim concentration-time curve from time zero to the last time point with quantifiable concentration (AUC0-4) during Week 1

Time frame:
Week 1
Reported as:
Mean · hr*pg/mL
Part B: Week 1 AUC0-4
hr*pg/mLPart B: 750 µg Romiplostim SC QWPart B: 750 µg Romiplostim SC Q2WPart B: 750 µg Romiplostim IV Q2W
Part B: Week 1 AUC0-4190000 ± 181000182000 ± 1110002030000 ± 838000
SecondaryPart B: Week 7 Cmax

Maximum observed serum concentration (Cmax) of romiplostim during Week 7.

Time frame:
Week 7
Reported as:
Mean · pg/mL
Part B: Week 7 Cmax
pg/mLPart B: 750 µg Romiplostim SC QWPart B: 750 µg Romiplostim SC Q2W
Part B: Week 7 Cmax785 ± 906357 ± 361
SecondaryPart B: Week 7 Ctrough

Measured romiplostim concentration at the end of the Week 7 dosing interval (Ctrough)

Time frame:
Week 7
Reported as:
Mean · pg/mL
Part B: Week 7 Ctrough
pg/mLPart B: 750 µg Romiplostim SC QWPart B: 750 µg Romiplostim SC Q2W
Part B: Week 7 Ctrough54.6 ± 21.020.1 ± 1.98
SecondaryPart B: Week 7 AUC0-4

Area under the romiplostim concentration-time curve from time zero to the last time point with quantifiable concentration (AUC0-4) during Week 7.

Time frame:
Week 7
Reported as:
Mean · hr*pg/mL
Part B: Week 7 AUC0-4
hr*pg/mLPart B: 750 µg Romiplostim SC QWPart B: 750 µg Romiplostim SC Q2W
Part B: Week 7 AUC0-457100 ± 6430035500 ± 36400
SecondaryPart B: Week 1 Tmax

Time at which the maximum concentration of romiplostum was observed after subcutaneous administration during Week 1

Time frame:
Week 1
Reported as:
Median · Hours
Part B: Week 1 Tmax
HoursPart B: 750 µg Romiplostim SC QWPart B: 750 µg Romiplostim SC Q2W
Part B: Week 1 Tmax24.0 (24 to 24)24.0 (24 to 24)
SecondaryPart B: Week 7 Tmax

Time at which the maximum concentration of romiplostum was observed after subcutaneous administration during Week 7

Time frame:
Week 7
Reported as:
Median · Hours
Part B: Week 7 Tmax
HoursPart B: 750 µg Romiplostim SC QWPart B: 750 µg Romiplostim SC Q2W
Part B: Week 7 Tmax24.0 (2 to 120)24.0 (24 to 72)
PrimaryPart A: Number of Participants With Adverse Events

The number of participants experiencing one or more adverse events during the treatment phase or extension phase of Part A.

Time frame:
Treatment period (4 weeks) plus treatment extension (1 year)
Reported as:
Number · Participants
Part A: Number of Participants With Adverse Events
ParticipantsPart A: 300 µg RomiplostimPart A: 700 µg RomiplostimPart A: 1000 µg RomiplostimPart A: 1500 µg Romiplostim
Part A: Number of Participants With Adverse Events6111115
PrimaryPart B: Number of Participants With Adverse Events

The number of participants experiencing one or more adverse events during the treatment phase or extension phase of Part B.

Time frame:
Treatment period (8 weeks) plus treatment extension (1 year)
Reported as:
Number · Participants
Part B: Number of Participants With Adverse Events
ParticipantsPart B: 750 µg Romiplostim SC QWPart B: 750 µg Romiplostim SC Q2WPart B: 750 µg Romiplostim IV Q2W
Part B: Number of Participants With Adverse Events10115

Adverse events

Collected over Every visit and up to 30 days after end of study (up to 64 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: 300 µg Romiplostim—2/6 (33.3%)6/6 (100%)
Part A: 700 µg Romiplostim—3/11 (27.3%)11/11 (100%)
Part A: 1000 µg Romiplostim—2/11 (18.2%)11/11 (100%)
Part A: 1500 µg Romiplostim—10/16 (62.5%)15/16 (93.8%)
Part B: 750 µg Romiplostim SC QW—1/11 (9.1%)10/11 (90.9%)
Part B: 750 µg Romiplostim SC Q2W—2/12 (16.7%)10/12 (83.3%)
Part B: 750 µg Romiplostim IV Q2W—2/5 (40%)4/5 (80%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventPart A: 300 µg RomiplostimPart A: 700 µg RomiplostimPart A: 1000 µg RomiplostimPart A: 1500 µg RomiplostimPart B: 750 µg Romiplostim SC QWPart B: 750 µg Romiplostim SC Q2WPart B: 750 µg Romiplostim IV Q2W
Cardiac arrestCardiac disorders0/60/110/110/160/110/121/5
Coronary artery dissectionCardiac disorders0/60/110/110/160/110/121/5
Rectal haemorrhageGastrointestinal disorders0/60/110/110/160/110/121/5
HypersensitivityImmune system disorders0/60/110/110/160/110/121/5
Subarachnoid haemorrhageNervous system disorders0/60/110/110/160/110/121/5
Lobar pneumoniaInfections and infestations1/60/110/110/160/110/120/5
PneumoniaInfections and infestations1/60/110/110/161/110/120/5
FallInjury, poisoning and procedural complications1/60/110/110/160/110/120/5
HyperkalaemiaMetabolism and nutrition disorders1/60/110/110/160/110/120/5
Musculoskeletal painMusculoskeletal and connective tissue disorders1/60/110/110/160/110/120/5
Most frequent other events
Showing 10 of 250
Most frequent other events
EventPart A: 300 µg RomiplostimPart A: 700 µg RomiplostimPart A: 1000 µg RomiplostimPart A: 1500 µg RomiplostimPart B: 750 µg Romiplostim SC QWPart B: 750 µg Romiplostim SC Q2WPart B: 750 µg Romiplostim IV Q2W
FatigueGeneral disorders4/65/110/113/164/111/120/5
DiarrhoeaGastrointestinal disorders3/61/112/115/161/110/120/5
Oedema peripheralGeneral disorders3/62/111/112/161/111/120/5
Back painMusculoskeletal and connective tissue disorders1/63/113/111/164/110/120/5
HeadacheNervous system disorders1/63/112/113/164/111/120/5
VomitingGastrointestinal disorders2/62/110/112/161/110/120/5
Upper respiratory tract infectionInfections and infestations2/61/111/111/160/110/120/5
ContusionInjury, poisoning and procedural complications2/61/111/113/162/110/120/5
DizzinessNervous system disorders2/62/111/111/160/111/120/5
HaematuriaRenal and urinary disorders2/61/110/110/160/110/120/5

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Part A: 300 µg RomiplostimPart A: 700 µg RomiplostimPart A: 1000 µg RomiplostimPart A: 1500 µg RomiplostimPart B: 750 µg Romiplostim SC QWPart B: 750 µg Romiplostim SC Q2WPart B: 750 µg Romiplostim IV Q2WTotal
Mean77.5 ± 3.368.2 ± 10.270.9 ± 14.268.9 ± 13.869.4 ± 6.372.1 ± 9.972.2 ± 4.370.7 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Part A: 300 µg RomiplostimPart A: 700 µg RomiplostimPart A: 1000 µg RomiplostimPart A: 1500 µg RomiplostimPart B: 750 µg Romiplostim SC QWPart B: 750 µg Romiplostim SC Q2WPart B: 750 µg Romiplostim IV Q2WTotal
Female052523118
Male6691199454
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: 300 µg RomiplostimPart A: 700 µg RomiplostimPart A: 1000 µg RomiplostimPart A: 1500 µg RomiplostimPart B: 750 µg Romiplostim SC QWPart B: 750 µg Romiplostim SC Q2WPart B: 750 µg Romiplostim IV Q2WTotal
White or Caucasian5119141010463
Black or African American00010102
Hispanic or Latino10010002
Asian00200002
Japanese00000000
American Indian or Alaska Native00000000
Aborigine00000000
Other00001113
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, Shammo J, Siegel R, Hu K, Franklin J, Berger DP. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol. 2010 Jan 20;28(3):437-44. doi: 10.1200/JCO.2009.24.7999. Epub 2009 Dec 14. PubMed 20008626 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2010, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2006
First posted
Mar 17, 2006
Start
Feb 2006
Primary completionActual
May 2008
CompletionActual
May 2008
Results first posted
Nov 19, 2010
Last update
Dec 16, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00303472
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Mar 17, 2006
Start date
Feb 2006
Primary completion
May 2008
Completion
May 2008
Results posted
Nov 19, 2010
Last update
Dec 16, 2013

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion